ClinicalTrials.gg
RecruitingNCT07208864Updated Sep 8, 2026

Efficacy of an AI System in Training Endoscopists to Assess Gastric Intestinal Metaplasia Via the EGGIM Score

An interventional study of AI-assisted EGGIM scoring and Conventional EGGIM scoring in Gastric Intestinal Metaplasia, sponsored by Qilu Hospital of Shandong University. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2026-09-08.

Sponsored by Qilu Hospital of Shandong University · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
8
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Metaplasia with a site in China — 6 open to participants now, 6 under way, none of them phase 3. Metaplasia · China.

Planned enrollment
12th of 12
8 · median 162
Started
2025
with 2 others
No phase
5 of 23
1 open now
Registered
21st of 23
by date
Lead sponsor
3 of 23
Qilu Hospital of Shandong University

Among the 23 studies in Metaplasia with a site in China, this one is the 12th largest by planned enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2025, is one of 5 with no phase, and was the 21st registered.

Metaplasia

45 studies on the registry are indexed under Metaplasia; 11 are open to participants now.

Browse Metaplasia studies →

Open to participants now

6 of the 23 studies in Metaplasia with a site in China are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 7 Metaplasia studies recruiting now, 4 set no upper age limit and 3 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Metaplasia with a site in China, or all of them as a file.
02

Study summary

This prospective randomized controlled trial with a crossover design incorporated image-enhanced endoscopy (IEE) videos demonstrating complete standardized examinations of five standard gastric areas (antrum greater curvature, antrum lesser curvature, incisura, corpus lesser curvature, and corpus greater curvature). Endoscopists were stratified by experience level and randomly assigned to either the AI-assisted scoring first group, which performed EGGIM scoring with AI assistance in the initial phase followed by conventional scoring after a washout period, or the conventional scoring first group, which completed the assessments in reverse order. The study primarily evaluated the training efficacy of the EGGIM-AI system for improving endoscopists' EGGIM scoring performance by comparing diagnostic accuracy metrics, including the area under the receiver operating characteristic curve (AUC), sensitivity, and specificity between groups at different study phases.

03

Conditions studied

  • Gastric Intestinal Metaplasia

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Endoscopists who have performed ≥50 image-enhanced endoscopy (IEE) procedures per year and demonstrated competency in performing standardized IEE.

Exclusion criteria

Exclusion Criteria:

Endoscopists who participated in data acquisition or were unblinded to patients' identifiable information and clinical data.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Outcomes assessor)
Enrollment
8 participants (estimated)

Study arms

  • Experimental
    AI-assisted scoring first group

    Endoscopists will first evaluate the videos with the assistance of the AI system via EGGIM score, and after the washout period, the videos will be evaluated again without the assistance of the AI system.

    Diagnostic Test: AI-assisted EGGIM scoring

  • Active comparator
    Conventional scoring first group

    Endoscopists will first evaluate the videos without the assistance of the AI system via EGGIM score, and after the washout period, the videos will be evaluated again with the assistance of the AI system.

    Diagnostic Test: Conventional EGGIM scoring

Interventions

  • Diagnostic testAI-assisted EGGIM scoring

    Endoscopists will evaluate the videos with the assistance of the AI system via EGGIM score.

  • Diagnostic testConventional EGGIM scoring

    Endoscopists will evaluate the videos without the assistance of the AI system via EGGIM score.

06

What researchers measure

Primary outcomes

  1. Efficacy of the EGGIM-AI system for improving endoscopists' EGGIM scoring performance

    Diagnostic accuracy metrics, including the area under the receiver operating characteristic curve (AUC), sensitivity, and specificity between groups at different study phases.

    Time frame: Through study completion, an average of 3 months

Secondary outcomes

  1. Performance of EGGIM scoring by endoscopists with varying experience levels

    Differences in AUC, sensitivity, and specificity of EGGIM scores between experienced and inexperienced endoscopists within each group at different phases.

    Time frame: Through study completion, an average of 3 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2025 (actual). Primary completion is estimated for Sep 2026, 10 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2025
First posted
Oct 6, 2025
StartActual
Nov 30, 2025
Primary completionEst.
Sep 30, 2026
CompletionEst.
Dec 31, 2026
Last update
Sep 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07208864
Responsible party
Sponsor
First posted
Oct 6, 2025
Start date
Nov 30, 2025
Primary completion
Sep 30, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Sep 8, 2026

Study contacts

Zhen Li
Contact
qilulizhen@sdu.edu.cn
86+18560086106

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion